# Kathy S. Albain

Source: https://onco.cc/people/kathy-albain/  
OnCo record `kathy-albain` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.

## Summary

Kathy Albain is Vice Chair for Clinical Trials Partnerships at SWOG and Professor of Medicine at Loyola University Chicago. A breast and lung medical oncologist specialising in genomic assays, she led SWOG 8814, the study of Oncotype DX in node-positive disease, co-led RxPONDER (SWOG S1007), and chaired SWOG trials in stage III lung cancer. Her papers include a Lancet Oncology retrospective analysis of the prognostic and predictive value of the 21-gene recurrence score in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy and the New England Journal of Medicine report of the 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. Her record also links to TAILORx.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Vice Chair, Clinical Trials Partnerships, SWOG; Professor of Medicine, Loyola University Chicago
- Specialisms: Breast cancer; Lung cancer; Genomic assays

## Sources

- SWOG leadership: https://www.swog.org/about/leadership
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Albain%20KS%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Kathy%20S.%20Albain

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Oncotype DX](https://onco.cc/drugs/oncotype-dx/)
- companies: [SWOG Cancer Research Network](https://onco.cc/companies/swog/)
- trials: [RxPONDER (SWOG S1007)](https://onco.cc/trials/rxponder/), [TAILORx](https://onco.cc/trials/tailorx/)

---
JSON: https://onco.cc/api/v1/entities/kathy-albain.json